Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists

被引:38
作者
Sepe, Valentina [1 ]
Festa, Carmen [1 ]
Renga, Barbara [2 ]
Carino, Adriana [2 ]
Cipriani, Sabrina [2 ]
Finamore, Claudia [1 ]
Masullo, Dario [1 ]
del Gaudio, Federica [3 ,4 ]
Monti, Maria Chiara [3 ]
Fiorucci, Stefano [2 ]
Zampella, Angela [1 ]
机构
[1] Univ Naples Federico II, Dept Pharm, I-80131 Naples, Italy
[2] Nuova Fac Med, Dept Surg & Biomed Sci, I-06132 Perugia, Italy
[3] Univ Salerno, PhD Program Drug Discovery & Dev, I-84084 Salerno, Italy
[4] Univ Salerno, Dept Pharm, I-84084 Salerno, Italy
关键词
FARNESOID-X-RECEPTOR; NUCLEAR RECEPTOR; OBETICHOLIC ACID; TGR5; LIGANDS; LIVER; IDENTIFICATION; DERIVATIVES; ACTIVATION; CHEMISTRY;
D O I
10.1038/srep19008
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Bile acids are the endogenous modulators of the nuclear receptor FXR and the membrane receptor GPBAR1. FXR represents a promising pharmacological target for the treatment of cholestatic liver disorders. Currently available semisynthetic bile acid derivatives cover the same chemical space of bile acids and therefore they are poorly selective toward BA receptors, increasing patient risk for adverse side effects. In this report, we have investigated around the structure of CDCA describing the synthesis and the in vitro and in vivo pharmacological characterization of a novel family of compounds modified on the steroidal tetracyclic core and on the side chain. Pharmacological characterization resulted in the identification of several potent and selective FXR agonists. These novel agents might add utility in the treatment of cholestatic disorders by potentially mitigating side effects linked to unwanted activation of GPBAR1.
引用
收藏
页数:11
相关论文
共 25 条
[1]   The TGR5 receptor mediates bile acid-induced itch and analgesia [J].
Alemi, Farzad ;
Kwon, Edwin ;
Poole, Daniel P. ;
Lieu, TinaMarie ;
Lyo, Victoria ;
Cattaruzza, Fiore ;
Cevikbas, Ferda ;
Steinhoff, Martin ;
Nassini, Romina ;
Materazzi, Serena ;
Guerrero-Alba, Raquel ;
Valdez-Morales, Eduardo ;
Cottrell, Graeme S. ;
Schoonjans, Kristina ;
Geppetti, Pierangelo ;
Vanner, Stephen J. ;
Bunnett, Nigel W. ;
Corvera, Carlos U. .
JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (04) :1513-1530
[2]   FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats [J].
Cipriani, Sabrina ;
Mencarelli, Andrea ;
Palladino, Giuseppe ;
Fiorucci, Stefano .
JOURNAL OF LIPID RESEARCH, 2010, 51 (04) :771-784
[3]   Exploitation of Cholane Scaffold for the Discovery of Potent and Selective Farnesoid X Receptor (FXR) and G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1) Ligands [J].
Festa, Carmen ;
Renga, Barbara ;
D'Amore, Claudio ;
Sepe, Valentina ;
Finamore, Claudia ;
De Marino, Simona ;
Carino, Adriana ;
Cipriani, Sabrina ;
Monti, Maria Chiara ;
Zampella, Angela ;
Fiorucci, Stefano .
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (20) :8477-8495
[4]   Farnesoid X Receptor Agonist for the Treatment of Liver and Metabolic Disorders: Focus on 6-ethyl-CDCA [J].
Fiorucci, S. ;
Cipriani, S. ;
Mencarelli, A. ;
Baldelli, F. ;
Bifulco, G. ;
Zampella, A. .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2011, 11 (09) :753-762
[5]   Targeting farnesoid X receptor for liver and metabolic disorders [J].
Fiorucci, Stefano ;
Rizzo, Gianni ;
Donini, Annibale ;
Distrutti, Eleonora ;
Santucci, Luca .
TRENDS IN MOLECULAR MEDICINE, 2007, 13 (07) :298-309
[6]   Targeting FXR in cholestasis: hype or hope [J].
Fiorucci, Stefano ;
Distrutti, Eleonora ;
Ricci, Patrizia ;
Giuliano, Vittorio ;
Donini, Annibale ;
Baldelli, Franco .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (12) :1449-1459
[7]  
Fiorucci S, 2012, FUTURE MED CHEM, V4, P877, DOI [10.4155/fmc.12.41, 10.4155/FMC.12.41]
[8]   Bile acid-activated receptors in the treatment of dyslipidemia and related disorders [J].
Fiorucci, Stefano ;
Cipriani, Sabrina ;
Baldelli, Franco ;
Mencarelli, Andrea .
PROGRESS IN LIPID RESEARCH, 2010, 49 (02) :171-185
[9]   Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders [J].
Fiorucci, Stefano ;
Mencarelli, Andrea ;
Palladino, Giuseppe ;
Cipriani, Sabrina .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2009, 30 (11) :570-580
[10]   Farnesoid X receptor agonists in biliary tract disease [J].
Fiorucci, Stefano ;
Baldelli, Franco .
CURRENT OPINION IN GASTROENTEROLOGY, 2009, 25 (03) :252-259